Fractyl Health Shares Are Trading Lower Amid Possible Volatility. The Company Yesterday Initially Spiked After It Announced FDA IDE Approval for the Revita Remain-1 Pivotal Study and Then Rebounded After Reporting Q4 Financial Results
在可能出現波動的情況下，Fractyl Health的股票交易價格走低。該公司昨天在宣佈FDA IDE批准Revita Remain-1關鍵研究後最初飆升，然後在公佈第四季度財務業績後反彈